Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma

Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.

Stoke Therapeutics Advances Dravet Syndrome Drug to Phase III Trials After FDA Lifts Partial Clinical Hold

Stoke Therapeutics, Dravet syndrome, Phase III trials, FDA, zorevunersen, SCN1A activator, orphan drug designation, rare pediatric disease designation

NewAmsterdam’s Obicetrapib Hits Primary Endpoint in Phase III HeFH Study, but Falls Short of Expectations

NewAmsterdam Pharma, Obicetrapib, CETP Inhibitor, Phase III Trial, Heterozygous Familial Hypercholesterolemia (HeFH), LDL Cholesterol, HDL Cholesterol, Cardiovascular Disease

FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search

Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership